Trials / Terminated
TerminatedNCT02834975
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that tumor cell killing by cytotoxic chemotherapy exposes the immune system to high levels of tumor antigens.The combination of Paclitaxel/Carboplatin and Pembrolizumab may result in deeper and more durable responses compared with standard chemotherapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab on Day 1 of each cycle. |
| DRUG | Paclitaxel | * NACT: Paclitaxel on Day 1 of each cycle; * ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol. |
| DRUG | Carboplatin | Carboplatin IV on Day 1 of each cycle. |
Timeline
- Start date
- 2016-12-22
- Primary completion
- 2022-09-01
- Completion
- 2022-12-01
- First posted
- 2016-07-15
- Last updated
- 2023-11-07
- Results posted
- 2023-11-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02834975. Inclusion in this directory is not an endorsement.